UY38755A - Inhibidores de la replicación del virus de inmunodeficiencia humana - Google Patents

Inhibidores de la replicación del virus de inmunodeficiencia humana

Info

Publication number
UY38755A
UY38755A UY0001038755A UY38755A UY38755A UY 38755 A UY38755 A UY 38755A UY 0001038755 A UY0001038755 A UY 0001038755A UY 38755 A UY38755 A UY 38755A UY 38755 A UY38755 A UY 38755A
Authority
UY
Uruguay
Prior art keywords
immunodeficiency virus
human immunodeficiency
virus replication
replication inhibitors
inhibitors
Prior art date
Application number
UY0001038755A
Other languages
English (en)
Spanish (es)
Inventor
Christiana Iwuagwu
P Gillis Eric
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of UY38755A publication Critical patent/UY38755A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001038755A 2019-06-19 2020-06-17 Inhibidores de la replicación del virus de inmunodeficiencia humana UY38755A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19

Publications (1)

Publication Number Publication Date
UY38755A true UY38755A (es) 2020-11-30

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038755A UY38755A (es) 2019-06-19 2020-06-17 Inhibidores de la replicación del virus de inmunodeficiencia humana

Country Status (33)

Country Link
US (2) US12129255B2 (https=)
EP (1) EP3986561B1 (https=)
JP (1) JP7628512B2 (https=)
KR (1) KR102932817B1 (https=)
CN (2) CN114245795B (https=)
AR (1) AR119174A1 (https=)
AU (1) AU2020295793B2 (https=)
BR (1) BR112021025655A2 (https=)
CL (1) CL2021003388A1 (https=)
CO (1) CO2021017479A2 (https=)
CR (1) CR20210664A (https=)
DK (1) DK3986561T3 (https=)
ES (1) ES2974541T3 (https=)
FI (1) FI3986561T3 (https=)
HR (1) HRP20240501T1 (https=)
HU (1) HUE065762T2 (https=)
IL (1) IL288750B2 (https=)
LT (1) LT3986561T (https=)
MA (1) MA56526B1 (https=)
MD (1) MD3986561T2 (https=)
MX (1) MX2021016149A (https=)
MY (1) MY206712A (https=)
PE (1) PE20220510A1 (https=)
PH (1) PH12021553180A1 (https=)
PL (1) PL3986561T3 (https=)
PT (1) PT3986561T (https=)
RS (1) RS65304B1 (https=)
SI (1) SI3986561T1 (https=)
SM (1) SMT202400153T1 (https=)
TW (1) TWI850403B (https=)
UA (1) UA128967C2 (https=)
UY (1) UY38755A (https=)
WO (1) WO2020254985A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025637A2 (pt) 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
BR112021025655A2 (pt) 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
MX2022003945A (es) * 2019-10-01 2022-04-25 Viiv Healthcare Co Metodo para tratar vih con cabotegravir y rilpivirina.
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
MX2024004551A (es) * 2021-10-13 2024-06-26 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363705B9 (en) 2001-02-02 2012-11-07 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL2212324T3 (pl) * 2008-07-02 2014-11-28 Avexa Ltd Związki posiadające właściwości przeciwwirusowe
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
US11541055B2 (en) * 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112021025655A2 (pt) 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana

Also Published As

Publication number Publication date
AR119174A1 (es) 2021-12-01
UA128967C2 (uk) 2024-12-11
MA56526B1 (fr) 2024-05-31
CN119039288A (zh) 2024-11-29
CN114245795A (zh) 2022-03-25
DK3986561T3 (da) 2024-03-04
US20210323967A1 (en) 2021-10-21
JP7628512B2 (ja) 2025-02-10
MX2021016149A (es) 2022-05-18
CA3143136A1 (en) 2020-12-24
ES2974541T3 (es) 2024-06-27
PE20220510A1 (es) 2022-04-07
PT3986561T (pt) 2024-03-15
JP2022537047A (ja) 2022-08-23
US20250019383A1 (en) 2025-01-16
IL288750B2 (en) 2025-04-01
IL288750B1 (en) 2024-12-01
HUE065762T2 (hu) 2024-06-28
CL2021003388A1 (es) 2022-09-30
EP3986561A1 (en) 2022-04-27
KR20220024608A (ko) 2022-03-03
LT3986561T (lt) 2024-04-25
RS65304B1 (sr) 2024-04-30
MY206712A (en) 2025-01-03
CN114245795B (zh) 2024-08-06
TWI850403B (zh) 2024-08-01
KR102932817B1 (ko) 2026-03-04
FI3986561T3 (fi) 2024-05-02
WO2020254985A1 (en) 2020-12-24
EP3986561B1 (en) 2024-02-14
PH12021553180A1 (en) 2022-11-07
PL3986561T3 (pl) 2024-06-10
CO2021017479A2 (es) 2022-04-19
MA56526A (fr) 2022-04-27
HRP20240501T1 (hr) 2024-07-05
SI3986561T1 (sl) 2024-04-30
US12129255B2 (en) 2024-10-29
AU2020295793B2 (en) 2023-07-06
SMT202400153T1 (it) 2024-05-14
IL288750A (en) 2022-02-01
CR20210664A (es) 2022-01-21
BR112021025655A2 (pt) 2022-02-01
AU2020295793A1 (en) 2022-01-20
TW202115055A (zh) 2021-04-16
MD3986561T2 (ro) 2024-06-30

Similar Documents

Publication Publication Date Title
UY38755A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CL2022002405A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
CO2025016290A2 (es) Compuestos anti-vih
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018000177A2 (pt) composto, composição, e, método para tratar a infecção pelo hiv.